Back to Massachusetts

S2035 • 2025

An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing

An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing

Taxes
Active

The official status still shows this bill as active or still awaiting another formal step.

Sponsor
Jason M. Lewis
Last action
2026-04-01
Official status
Reporting date extended to Thursday June 25, 2026
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing

An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing By Mr.

What This Bill Does

  • An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing By Mr.
  • Lewis, a petition (accompanied by bill, Senate, No.
  • 2035) of Jason M.
  • Lewis and Rebecca L.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-04-01 Senate

    Reporting date extended to Thursday June 25, 2026

  2. 2025-10-21 Joint

    Hearing scheduled for 10/28/2025 from 01:00 PM-05:00 PM in B-2

  3. 2025-02-27 Senate

    Referred to the committee on Revenue

  4. 2025-02-27 House

    House concurred

Official Summary Text

An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
By Mr. Lewis, a petition (accompanied by bill, Senate, No. 2035) of Jason M. Lewis and Rebecca L. Rausch for legislation to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing. Revenue.

Current Bill Text

Read the full stored bill text
×

Bill S.2035

Section 1 of chapter 63 of the General Laws, as appearing in the 2020 Official Edition, is hereby amended by striking items (e) and (f) under the definition of “net income” and inserting in place thereof the following:-

(e) the deduction allowed by section 199 of the Code;

(f) the deduction described in section 163(e)(5) of the Code, to the extent increased by amendments to section 163(e)(5)(F) and section 163(i)(1) of the Code, inserted by section 1232 of the American Recovery and Reinvestment Act of 2009; or

(g) the deduction described in section 162(a) of the Code, to the extent that this deduction applies to direct consumer advertising of prescription drugs, which shall include all direct and indirect costs incurred or paid relating to advertising prescription drugs and devices to patients in Massachusetts, including media advertising, coupons, outreach and persistency programs, and any other forms of marketing or advertising directed to persons other than licensed prescribers. For amounts paid or incurred in national or regional programs, the amount disallowed shall be the ratable share of expenses directed to Massachusetts residents.

The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

Close